EHA 2023 Congress

Octapharma Update-In-Hematology

Share this page


Chronic Lymphocytic Leukemia (CLL) and Beyond

Management of the Infection Burden

Friday, 9 June, 2023
16:15 - 17:45 CEST
Room: Illusion

The overall survival of patients with chronic lymphocytic leukemia (CLL) has improved significantly over the years; however, the clinical course remains highly heterogeneous, and infections continue to be a major cause of death. 

Given the high risk of infection in patients with CLL, infection prophylaxis has to play a key role. Presently, immunoglobulin replacement therapy (IgRT) is recommended to patients with low IgG levels who have already experienced at least two severe infections within a year. Recent clinical developments bring novel perspectives to this approach.

During this session, the results of a real-world retrospective study analyzing the infection risk in CLL patients based on their history of infections and treatments will be discussed. Emphasis will be placed on how infections of varying degrees of severity are modulated after initiation of IgRT. Subsequently, a second study based on a sample analysis representative of the practice in Germany will detail the risk factors for infections in CLL patients and highlight the impact of the adherence to IgG substitution guidelines on infectious episodes. Then, real-world data on the use of subcutaneous immunoglobulin therapy in CLL patients suffering from antibody deficiency will be presented and therapies under development will be reviewed.

In the last part of the session, the audience and faculty will have the opportunity to exchange views and debate on challenging cases of CLL-associated infections. Questions from the audience will be answered at the end of the session.

To attendt his session, register to the EHA 2023 Hybrid Congress.




Welcome and introduction

Chair: Stephan Stilgenbauer (Ulm, Germany)

Identifying the Risk of Infections in CLL – Impact of Treatment and Supportive Care

Caspar da Cunha-Bang (Copenhagen, Denmark)

Reducing the Severity of Infections Associated with CLL – The Importance of IgG Substitution Guidelines

Hartmut Link (Kaiserslautern, Germany)

Targeting Primary Infection Prophylaxis in the Context of CLL – Daily Practice and Clinical Studies

Livio Trentin (Padua, Italy)

Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL

All Faculty

Closing Remarks

Stephan Stilgenbauer (Ulm, Germany)

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.

Meet the speakers

Chair: Stephan Stilgenbauer

Ulm University, Germany

Caspar da Cunha-Bang

Rigshospitalet, Copenhagen, Denmark

Hartmut Link

Hematology Oncology Kaiserslautern, Germany

Livio Trentin

University of Padua, Italy

Learn more about SID

Visit our information hub to learn more about secondary immunodeficiencies and hematological malignancies.

Science Hub

View more lectures about immunodeficiencies related to hematological malignancies on Science Hub.